FDA Approves Large Studies of Ecstasy to Treat PTSD
Large-scale Phase 3 clinical trials of the illegal party drug Ecstasy as a treatment for post-traumatic stress disorder (PTSD) were approved Tuesday by the U.S. Food and Drug Administration.
Some small studies have yielded promising results. If the new trials are successful, Ecstasy (MDMA) could be approved as a prescription drug for PTSD, The New York Times reported.
An FDA spokeswoman declined to comment on the matter, citing rules that forbid providing information about drugs under development.
Click here to Read the full article: FDA Approves Large Studies of Ecstasy to Treat PTSD
Share this entry
- Protected: The American Health Council Appoints Erin Grimes to the Occupational Therapy Board January 21, 2019
- The American Health Council appoints Ms. Kelby Kramer, R.Ph to the Healthcare Board January 15, 2019
- The American Health Council Appoints Ms. Brittney Godwin Tice to the Nursing Board January 11, 2019
- Protected: The American Health Council Appoints Dr. Adrienne Steckler to the Physician Board January 10, 2019
- Protected: The American Health Council Appoints Ms. Hannah Walker to the Industry Board January 10, 2019
- Protected: The American Health Council Welcomes New Affiliate, Dr. John Rector to the Physical Therapy Board January 10, 2019